Skip to main content
. 2015 Jan 26;33(7):723–731. doi: 10.1200/JCO.2014.56.5119

Fig 2.

Fig 2.

Kaplan-Meier estimates of (A) overall survival, (B) radiographic progression-free survival (PFS), and (C) time to prostate-specific antigen (PSA) progression. (B) Radiographic progressive disease (rPD) was determined by a central imaging center based on protocol definition, not per identification by investigator. Alt, alternate.